| Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis S Turajlic, K Litchfield, H Xu, R Rosenthal, N McGranahan, JL Reading, ... The lancet oncology 18 (8), 1009-1021, 2017 | 850 | 2017 |
| Clinical relevance of host immunity in breast cancer: from TILs to the clinic P Savas, R Salgado, C Denkert, C Sotiriou, PK Darcy, MJ Smyth, S Loi Nature reviews Clinical oncology 13 (4), 228-241, 2016 | 828 | 2016 |
| Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis P Savas, B Virassamy, C Ye, A Salim, CP Mintoff, F Caramia, R Salgado, ... Nature medicine 24 (7), 986-993, 2018 | 817 | 2018 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 678 | 2017 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 605 | 2017 |
| Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib … R Salgado, C Denkert, C Campbell, P Savas, P Nuciforo, C Aura, ... JAMA oncology 1 (4), 448-455, 2015 | 598 | 2015 |
| RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune … S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ... Clinical Cancer Research 22 (6), 1499-1509, 2016 | 530 | 2016 |
| Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade IG House, P Savas, J Lai, AXY Chen, AJ Oliver, ZL Teo, KL Todd, ... Clinical Cancer Research 26 (2), 487-504, 2020 | 415 | 2020 |
| Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of … SJ Luen, R Salgado, S Fox, P Savas, J Eng-Wong, E Clark, A Kiermaier, ... The Lancet Oncology 18 (1), 52-62, 2017 | 307 | 2017 |
| Pervasive chromosomal instability and karyotype order in tumour evolution TBK Watkins, EL Lim, M Petkovic, S Elizalde, NJ Birkbak, GA Wilson, ... Nature 587 (7832), 126-132, 2020 | 270 | 2020 |
| Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer E Nolan, P Savas, AN Policheni, PK Darcy, F Vaillant, CP Mintoff, ... Science translational medicine 9 (393), eaal4922, 2017 | 270 | 2017 |
| Relevance of tumor-infiltrating lymphocytes in breast cancer S Dushyanthen, PA Beavis, P Savas, ZL Teo, C Zhou, M Mansour, ... BMC medicine 13, 1-13, 2015 | 256 | 2015 |
| The genomic landscape of breast cancer and its interaction with host immunity S Luen, B Virassamy, P Savas, R Salgado, S Loi The Breast 29, 241-250, 2016 | 252 | 2016 |
| Tissue-resident memory T cells in breast cancer control and immunotherapy responses A Byrne, P Savas, S Sant, R Li, B Virassamy, SJ Luen, PA Beavis, ... Nature reviews Clinical oncology 17 (6), 341-348, 2020 | 193 | 2020 |
| Combined CDK4/6 and PI3Kα inhibition is synergistic and immunogenic in triple-negative breast cancer ZL Teo, S Versaci, S Dushyanthen, F Caramia, P Savas, CP Mintoff, ... Cancer research 77 (22), 6340-6352, 2017 | 171 | 2017 |
| Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning F Klauschen, KR Müller, A Binder, M Bockmayr, M Hägele, P Seegerer, ... Seminars in cancer biology 52, 151-157, 2018 | 153 | 2018 |
| The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program “CASCADE” P Savas, ZL Teo, C Lefevre, C Flensburg, F Caramia, K Alsop, M Mansour, ... PLoS medicine 13 (12), e1002204, 2016 | 146 | 2016 |
| The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG … JK Mooi, P Wirapati, R Asher, CK Lee, P Savas, TJ Price, A Townsend, ... Annals of Oncology 29 (11), 2240-2246, 2018 | 143 | 2018 |
| Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer SJ Luen, P Savas, SB Fox, R Salgado, S Loi Pathology 49 (2), 141-155, 2017 | 133 | 2017 |
| Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Z Kos, E Roblin, RS Kim, S Michiels, BD Gallas, W Chen, KK van de Vijver, ... NPJ breast cancer 6 (1), 17, 2020 | 131 | 2020 |
Stephen LuenPeter MacCallum Cancer Centre, University of MelbourneПотвърден имейл адрес: petermac.org
